United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - emicizumab - solution for injection - 30mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - emicizumab - solution for injection - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - emicizumab - solution for injection - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - emicizumab - solution for injection - 150mg/1ml

European Union - English - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemophilia a - antihemorrhagics - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype.hemlibra can be used in all age groups.

Canada - English - Health Canada

hoffmann-la roche limited - emicizumab - solution - 30mg - emicizumab 30mg - antihemorrhagic agents, miscellaneous

Canada - English - Health Canada

hoffmann-la roche limited - emicizumab - solution - 60mg - emicizumab 60mg - antihemorrhagic agents, miscellaneous

Canada - English - Health Canada

hoffmann-la roche limited - emicizumab - solution - 105mg - emicizumab 105mg - antihemorrhagic agents, miscellaneous

Canada - English - Health Canada

hoffmann-la roche limited - emicizumab - solution - 150mg - emicizumab 150mg - antihemorrhagic agents, miscellaneous

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - emicizumab - solution for injection - emicizumab 150 mg / 1 ml - emicizumab - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with hemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.